前蛋白转化酶枯草杆菌蛋白酶/溶菌素9抑制剂治疗高胆固醇血症的经济性评价系统综述  

A systematic review of the cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibitors in the treatment of cardiovascular diseases

作　　者：孙凌垚 王文珊 王心茹 袁方哲 顾钰祺 谭玉洁 田磊[1] SUN Ling-yao;WANG Wen-shan;WANG Xin-ru;YUAN Fang-zhe;GU Yu-qi;TAN Yu-jie;TIAN Lei(School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing 210009,China)

机构地区：[1]中国药科大学国际医药商学院,南京210009

出　　处：《中国新药杂志》2025年第7期778-784,共7页Chinese Journal of New Drugs

基　　金：江苏高校哲学社会科学研究一般项目:基于医保视角的医疗服务诊疗项目的综合效果评估与监管路径研究(2020SJA0076)。

摘　　要：目的:探究前蛋白转化酶枯草杆菌蛋白酶/溶菌素9(proprotein convertase subtilisin/kexin type 9,PCSK9)抑制剂药物经济性评价的方法。方法:检索从建库至2024年1月15日PubMed,Embase,Scopus,Cochrane Library和Web of science数据库中有关PCSK9抑制剂经济学研究的文献,并使用2022年版综合卫生经济评价报告标准(Consolidated Health Economic Evaluation Reporting Standards,CHEERS)对纳入的文献进行评估。结果:30篇关于PCSK9抑制剂药物治疗心血管疾病的经济学评价研究中27篇采用了模型法进行经济学评价,主要使用马尔可夫模型,涵盖了多个研究时限和健康状态数量。23篇文献通过低密度脂蛋白胆固醇(low-density lipoproteins-cholesterol,LDL-C)水平降低进行外推来评估药效,23篇文献未考虑药物的不良反应。结论:现有文献主要通过马尔可夫模型对药物的经济性进行评价,在药物效果指标的选择、药物不良反应是否纳入分析等方面存在局限性。Objective:To explore methodologies for the economic evaluation of proprotein convertase subtilisin/kexin type 9(PCSK9) inhibitors.Methods:A literature search was conducted from inception until January 15,2024,across PubMed,Embase,Scopus,Cochrane Library,and Web of Science databases to identify studies focusing on the economic aspects of PCSK9 inhibitors.The included studies were evaluated using the 2022 version of the Consolidated Health Economic Evaluation Reporting Standards(CHEERS).Results:Among 30 economic evaluation studies of PCSK9 inhibitors for the treatment of cardiovascular disease,27 utilized modeling for economic assessment,predominantly employing Markov models.These studies varied in terms of duration and health state quantities.In 23 studies,LDL-C reduction was extrapolated for efficacy assessment,while adverse drug reactions were not considered.Conclusion:The current literature mainly evaluates the economic value of drugs using Markov models,but there are limitations in the selection of drug efficacy indicators,and whether adverse drug reactions are included in the analysis.

关 键 词：前蛋白转化酶枯草杆菌蛋白酶/溶菌素9抑制剂 经济性 方法学 系统综述 

分 类 号：R972[医药卫生—药品]